CRISPR-Cas-based activation of PPARGC1A boosts endogenous mitochondria and enhances cardiac function after myocardial infarction - PubMed
a day ago
- #cardiac recovery
- #mitochondrial biogenesis
- #CRISPRa
- CRISPR-Cas-based activation of PPARGC1A enhances mitochondrial function and cardiac recovery post-myocardial infarction (MI).
- PPARGC1A activation via CRISPRa increases mitochondrial biogenesis, ATP production, and bioenergetics in human cardiomyocytes.
- In vivo studies show CRISPRa targeting PPARGC1A improves heart ejection fraction after acute MI.
- CRISPRa also boosts mitochondrial function in adult human hearts, including those diagnosed with heart failure (HF).
- This study is the first to demonstrate that CRISPRa-mediated gene activation can improve heart function post-MI.